Replies to post #32004 on Revive Therapeutics Ltd (RVVTF)

[its only money]

Reiko.....Im not saying any of that is going to happen I was only asking a question because what I seen on some other boards....I didnt ask on those boards because this is the only one im signed up on and also from reading some of the other boards I dont want to be part of the shit show they are.....the people here seem to be more knowledgeable and do great DD and explain it to where a newbie like me can kinda understand ......besides they invited me to the party once we are rich,I will always have their backs.

[uksausage]

If the company has run out of authorized shares it cannot sell shares (technically not even ina convertible loan). So it has two options :
A) increase authorized shares , normally allowed once a year and needs a shareholder vote.
B) do a reverse split so authorized share count stays same but there are now half as many issued (if 2:1 reverse split) allowing those “new” shares to be sold and issued.

If the re is specific use for the funds it can work, or if it is associated with NASDAQ listing but 9 out of 10 just means more , faster dilution.

Option A sometimes sees companies with 10s of billions of shares (BIEL comes to mind)

[Ecomike]

Nice run down, on how they properly funded $RVVTF already.

There is nothing wrong with raising money at higher share prices and investing it in growth and expansion:

Why would a reverse split be necessary to procure funding? In February 2021, Revive raised $23,000,000 in an Offering. ("46,000,000 units (“Units”) at a price of $0.50 per Unit for aggregate gross proceeds of $23,000,000")

("Each Unit is comprised of one common share of the Company (a “Common Share”) and one common share purchase warrant (a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share at an exercise price of $0.70 per Common Share until February 12, 2024. If the daily volume weighted average trading price of the Common Shares on the Canadian Securities Exchange (the “Exchange”) is greater than $1.10 for the preceding ten (10) consecutive trading days, the Company may accelerate the expiry date of the Warrants to a date that is at least 30 trading days following the date on which the Company issues a press release announcing the reduced warrant term.")

If we see favorable results with Bucillamine then Revive's share price will reflect the favorable results. Revive could then procure additional funding through the warrants or do a similar Offering at a higher share price.

NVS-Novartis, one of dividend paying biotechs, has a nearly 3 Billion share OS and share prices hit over $90/share last month.

$RVVTF could up list to NYSE or Nasdaq at $3 to $4/share, after a rally to $5+/share and cash raise at $3 to $4/share with one news event. FDA EUA approval of #Bucillamine.